# ACE inhibitors

Drug · id `cardio:ace-inhibitors` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: ACE inhibitor; Angiotensin-converting enzyme inhibitors

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure; Heart failure  

## In plain language

A class of medicines whose main uses are treating high blood pressure and heart failure. MeSH says they work mainly by inhibiting the renin-angiotensin system, and cause mostly widening of blood vessels and a mild loss of salt in the urine without changing the heart rate. The US label read for one ACE inhibitor also lists lowering the risk of death when treatment starts within 24 hours of a heart attack in people whose circulation is stable, and carries a boxed warning that these drugs can cause injury and death to the developing fetus.

## Technical summary

Class page. MeSH descriptor D000806 (Angiotensin-Converting Enzyme Inhibitors, last updated 2026-01-01) is an exact match, and its scope note gives the class description. The label read is the US prescribing label of one brand-name lisinopril tablet (application NDA019777, effective 2025-01-02 in openFDA). It calls the medicine an ACE inhibitor and lists hypertension (adults and pediatric patients 6 years of age and older), adjunct therapy for heart failure and reduction of mortality in a window after acute myocardial infarction. A separate claim records its boxed warning on fetal toxicity; the recipient of that risk is the fetus. One label stands for one product, so other members of the class may list other uses, and no other label was read. This page gives no dose, no trial result and no guideline statement. Medicines of the class that have their own pages are filed under it.

## Claims, with the population each applies to

## Context: The developing fetus, for a person taking an ACE inhibitor during pregnancy, as described in a US label boxed warning

Recipient: Fetal; Population: The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.; Care setting: Prescription medicine, as described in the US label; Geography: United States (US drug label); Life stage: Fetus during pregnancy; the passage read gives no gestational ages; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The same US label of ZESTRIL carries a boxed warning titled fetal toxicity. It says that drugs acting directly on the renin-angiotensin system can cause injury and death to the developing fetus.

- Category: Safety
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Fetal; Population: The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.; Care setting: Prescription medicine, as described in the US label; Geography: United States (US drug label); Life stage: Fetus during pregnancy; the passage read gives no gestational ages; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records the fetal-risk statement of the label's boxed warning only. The warning also tells prescribers what to do when pregnancy is detected; that instruction is not repeated here. Other warnings, contraindications and interactions of the label were not recorded, and no pregnancy or lactation guidance is given. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-09
- Sources:
  1. Supports: openFDA drug label record for ZESTRIL (lisinopril tablets), Upsher-Smith Laboratories, LLC label: indications and class description (Regulator, edition The openFDA drug label record for set id 838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8 (manufacturer Upsher-Smith Laboratories, LLC, application NDA019777), returned on 2026-11-09. The label text is dated 2025-01-02 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\]. Retrieved 2026-11-09T13:17:27Z. Source state: Current. Version fingerprint: 19d3c7aeb72318fb767e48d426a1cb5c0715b2f2de82e0028467c20b5e469335.
     How it applies: The boxed warning title and its fetal-injury statement.
  2. Background: openFDA drug label record for ZESTRIL (lisinopril tablets), Upsher-Smith Laboratories, LLC label: indications and class description (Regulator, edition The openFDA drug label record for set id 838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8 (manufacturer Upsher-Smith Laboratories, LLC, application NDA019777), returned on 2026-11-09. The label text is dated 2025-01-02 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:17:27Z. Source state: Current. Version fingerprint: 19d3c7aeb72318fb767e48d426a1cb5c0715b2f2de82e0028467c20b5e469335.
     How it applies: Effective date of the label text read, 20250102.

## Context: People with hypertension (adults and pediatric patients 6 years and older), heart failure or a recent heart attack, as described in the US label of an ACE inhibitor

Recipient: Mixed recipients; Population: Patients described in the indications section of the label: adults and pediatric patients 6 years of age and older with hypertension, patients with systolic heart failure, and hemodynamically stable patients within 24 hours of acute myocardial infarction.; Care setting: Prescription medicine, as described in the US label; Geography: United States (US drug label); Life stage: Adults, and for hypertension also pediatric patients 6 years of age and older, as the label states; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of ZESTRIL (lisinopril tablets, Upsher-Smith Laboratories, application NDA019777; the version dated 2025-01-02 in openFDA) calls the medicine an angiotensin converting enzyme (ACE) inhibitor. It lists treating hypertension in adults and pediatric patients 6 years of age and older, adjunct therapy for heart failure (its detailed text says to reduce signs and symptoms of systolic heart failure), and reducing mortality in hemodynamically stable patients within 24 hours of acute myocardial infarction. MeSH describes the class in the same terms, as drugs whose main indications are the treatment of hypertension and heart failure.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Mixed recipients; Population: Patients described in the indications section of the label: adults and pediatric patients 6 years of age and older with hypertension, patients with systolic heart failure, and hemodynamically stable patients within 24 hours of acute myocardial infarction.; Care setting: Prescription medicine, as described in the US label; Geography: United States (US drug label); Life stage: Adults, and for hypertension also pediatric patients 6 years of age and older, as the label states; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Other ACE inhibitor labels list different uses. The label's contraindications, other warnings, interactions and dosing were not recorded; its boxed warning is recorded in a separate claim. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-09
- Sources:
  1. Supports: openFDA drug label record for ZESTRIL (lisinopril tablets), Upsher-Smith Laboratories, LLC label: indications and class description (Regulator, edition The openFDA drug label record for set id 838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8 (manufacturer Upsher-Smith Laboratories, LLC, application NDA019777), returned on 2026-11-09. The label text is dated 2025-01-02 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-09T13:17:27Z. Source state: Current. Version fingerprint: 19d3c7aeb72318fb767e48d426a1cb5c0715b2f2de82e0028467c20b5e469335.
     How it applies: The label sentence that calls the medicine an ACE inhibitor and the hypertension, heart failure (systolic heart failure in section 1.2) and acute myocardial infarction uses.
  2. Background: openFDA drug label record for ZESTRIL (lisinopril tablets), Upsher-Smith Laboratories, LLC label: indications and class description (Regulator, edition The openFDA drug label record for set id 838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8 (manufacturer Upsher-Smith Laboratories, LLC, application NDA019777), returned on 2026-11-09. The label text is dated 2025-01-02 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:17:27Z. Source state: Current. Version fingerprint: 19d3c7aeb72318fb767e48d426a1cb5c0715b2f2de82e0028467c20b5e469335.
     How it applies: Effective date of the label text read, 20250102.
  3. Supports: MeSH scope note for descriptor D000806 (Angiotensin-Converting Enzyme Inhibitors) (Dataset, edition MeSH linked-data record of the preferred concept M0001207 of descriptor D000806, fetched 2026-10-25. The scope note is on this concept record, not on the descriptor record.) <https://id.nlm.nih.gov/mesh/M0001207>
     Locator: scopeNote.@value. Retrieved 2026-10-25T15:27:58Z. Source state: Current. Version fingerprint: e0f6d57f67dfdc38977aa3de8fe4fc3ea23b840a72635886b2966506da249e97.
     How it applies: MeSH scope note: main indications of the class.

## Connected pages

- A US label lists treating high blood pressure as an indication: Hypertension (high blood pressure) (`core:hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-zestril-label-indications` and its context]
- A US label lists adjunct therapy for heart failure as an indication: Heart failure (`cardio:heart-failure`) [a claim, not a settled fact; see claim `cardio:claim-fda-zestril-label-indications` and its context]
- A US label lists a mortality-reduction use after a heart attack: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`) [a claim, not a settled fact; see claim `cardio:claim-fda-zestril-label-indications` and its context]
- A US label of the class lists reducing signs and symptoms of systolic heart failure: Heart failure with reduced ejection fraction (HFrEF) (`cardio:hfref`)
- Reading path on high blood pressure that names this class; a US label of the class lists high blood pressure: From a high blood pressure reading to stroke prevention (`cardio:reading-path-high-bp`)
- Patient guide on high blood pressure that names this class; a US label of the class lists high blood pressure: Newly diagnosed high blood pressure (`cardio:guide-new-high-blood-pressure`)
- Blood pressure lowering medicine, the care strategy: Blood pressure lowering medicine (`cardio:bp-lowering-medicine`)
- Heart failure medicine regimen: Four-class medicine regimen in heart failure (guideline-directed medical therapy) (`cardio:hfref-four-medicine-regimen`)
- Files under this front: Medicines (`cardio:front-medicines`)
- Has subtype: Enalapril (`cardio:enalapril`)
- Has subtype: Lisinopril (`cardio:lisinopril`)
- Has subtype: Ramipril (`cardio:ramipril`)
- Related to: Ranolazine (`cardio:ranolazine`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 1 registry trial

## Provenance

Content hash: 2a216bbdb6c4bbc95eaccf86fd2a28bfc83992fc469a4dcc9ff33e2b28ece90e
Last substantive edit: 2026-11-09
Evidence last checked: 2026-11-09
